

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **RESIGNATION OF A NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Ocumension Therapeutics (the “**Company**”) hereby announces that Ms. Yumeng WANG (“**Ms. Wang**”) has resigned as a non-executive Director on the date of this announcement with immediate effect, as she decided to devote more time to her other engagements.

Ms. Wang has confirmed that she has no disagreement with the Board and there is no other matter in connection with her resignation as a non-executive Director that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Her resignation will not affect the operation of the Board and the Company.

The Board would like to take this opportunity to express its gratitude to Ms. Wang for her valuable contributions to the Company during her tenure of service.

Pursuant to Rule 13.92 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), the Stock Exchange will not consider diversity to be achieved for a single gender board. Following the resignation of Ms. Wang, the Company does not have a board with different genders, and hence fails to meet the requirement set out in Rule 13.92 of the Listing Rules.

The Board will make its best endeavors to identify a suitable female candidate for appointment as a Director as soon as practicable and in any event within three months from the effective date of Ms. Wang’s resignation, in order to ensure compliance with the requirement in relation to gender diversity for members of board under Rule 13.92 of the Listing Rules. Further announcement(s) will be made by the Company in relation to the above as and when appropriate.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, October 21, 2024

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI and Mr. Yanling CAO as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.*